Document is current
Any future updates will be listed below
-
Authors
Oizumi, Satoshi https://orcid.org/0000-0002-9742-1818
Takamura, Kei
Harada, Toshiyuki
Tachihara, Motoko
Morikawa, Naoto
Honda, Ryoichi
Watanabe, Satoshi
Asao, Tetsuhiko
Kunisaki, Mamoru
Fukuhara, Tatsuro
Noro, Rintaro
Kikuchi, Eiki
Tsutani, Yasuhiro
Tenma, Toshiyuki
Kobayashi, Kunihiko
Dosaka-Akita, Hirotoshi
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000008707 at UMIN JapanDocuments that mention this clinical trial
Phase II study of carboplatin–paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024
https://doi.org/10.1007/s10147-021-02113-5
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (15K09164)
- License Information
-
More Information
Article History
Received: 30 September 2021
Accepted: 26 December 2021
First Online: 29 January 2022
Declarations
:
: SO received honoraria from AstraZeneca and Eli Lilly and research funding from Abbvie, Amgen, AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Kissei Pharmaceutical, Ono Pharmaceutical, Pfizer<i>,</i> Merck Biopharma, Sanofi, Taiho Pharmaceutical, and Takeda Pharmaceutical; MT received honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly, MSD, and Ono Pharmaceutical and research funding from AstraZeneca; SW received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, MSD, Novartis, Ono Pharmaceutical, Pfizer, and Taiho Pharmaceutical and research funding from AstraZeneca and Boehringer Ingelheim; TA received honoraria from AstraZeneca, Boehringer Ingelheim, Chugai Pharmaceutical, Eli Lilly, MSD, Ono Pharmaceutical, Taiho Pharmaceutical, and Takeda Pharmaceutical; RN received honoraria from AstraZeneca and Novartis; YT received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Ono Pharmaceutical, and Taiho Pharmaceutical; KK received honoraria from AstraZeneca; All other authors declare that they have no conflicts of interest.
